Last updated: March 5, 2025 FDA milestones: Aug 9, 2024 — initial 2 mg approval (≥30 kg); Mar 5, 2025 — 1 mg pediatric expansion (1 mg for 15 to <30 kg).
Looking for daily control while Neffy covers emergencies? See where sublingual immunotherapy (SLIT) fits for long‑term relief:
-
Pollen allergies: at‑home SLIT overview and results (Wyndly pollen immunotherapy)
-
Pet dander (cat/dog): needle‑free pet allergy program (Wyndly pet SLIT)
-
Dust mites: symptoms, testing, and SLIT options (Dust mite guide)
Why Neffy exists (and when to use it)
Neffy is the first FDA‑approved epinephrine delivered as a nasal spray for the emergency treatment of Type I allergic reactions, including life‑threatening anaphylaxis. Initial approval (2 mg) was granted on August 9, 2024 for adults and children who weigh at least 30 kg (≈66 lb). On March 5, 2025, FDA expanded use to a 1 mg dose for children 4+ years who weigh 15 to <30 kg (≈33 to <66 lb). These are rescue‑only indications for acute reactions—not a daily controller.
What Neffy does vs. what it doesn’t
| Neffy can… | Neffy cannot… |
|---|---|
| Deliver epinephrine rapidly during anaphylaxis in eligible patients (age ≥4 years and weight ≥15 kg). | Prevent future reactions or control day‑to‑day environmental allergies. |
| Be used as an alternative to injectable epinephrine for those who meet label criteria. | Replace ongoing medical care after a dose—emergency evaluation is still required. |
| Be repeated once after 5 minutes if symptoms persist or return (use a new device). | Be used more than twice in sequence without direct medical supervision. |
Key use points (per label): carry two devices; do not prime; insert fully into one nostril; avoid sniffing during/after actuation; give a second dose with a new device into the same nostril starting 5 minutes after the first if symptoms continue. See full Prescribing Information and Instructions for Use for details.
Who is eligible (doses by weight)
-
2 mg: adults and children who weigh ≥30 kg (≥66 lb).
-
1 mg: children aged ≥4 years who weigh 15 to <30 kg (33 to <66 lb).
FDA notes the intranasal route may reduce barriers (such as needle‑related delays) but it is still epinephrine for emergencies only.
Regulatory timeline for context: 2 mg approval on Aug 9, 2024; 1 mg pediatric expansion on Mar 5, 2025.
Safety, limits, and after‑care
-
Always seek emergency medical help after use; monitoring and additional care may be needed.
-
Carry two devices at all times; some patients require a second dose.
-
Use caution in patients with certain cardiac diseases or on interacting medicines; absorption can be affected by structural/anatomical nasal issues; see Warnings/Precautions in the label.
-
Not studied for children under 4 years or under 15 kg.
Authoritative resources include the FDA approval announcement and Prescribing Information/IFU.
How Neffy fits with long‑term allergy control
Neffy treats an emergency; it does not modify your immune system or control daily environmental allergy symptoms. For long‑term control of environmental allergies (pollen, dust mites, pets, mold), disease‑modifying immunotherapy is the evidence‑based option:
- Sublingual immunotherapy (SLIT) drops/tablets retrain the immune system for durable relief without injections and can be used at home under physician guidance. See Wyndly’s clinical overview and evidence summaries.
Wyndly’s doctor‑led programs personalize SLIT to your tested triggers and provide ongoing support, complementing your emergency‑only epinephrine plan.
Quick checklist (practical use)
-
Confirm weight‑appropriate dose (1 mg for 15–<30 kg; 2 mg for ≥30 kg).
-
At first signs of anaphylaxis, administer one spray in one nostril. Avoid sniffing. If symptoms persist/worsen after 5 minutes, repeat with a new device in the same nostril.
-
Call 911 or seek emergency care immediately after using Neffy.
-
After recovery, review your anaphylaxis action plan with your clinician and ensure you also have a plan for daily control (e.g., SLIT) if environmental allergies are a problem.
Official information hubs
-
FDA press announcement (indication, rationale, and access): see FDA resources for Neffy approval.
-
Prescribing Information and instructions (administration, warnings, dosing): see official Prescribing Information.
-
Patient‑facing safety and “how to use” education: see manufacturer and official guidelines.
Key takeaway: Neffy is for emergency rescue only. Pair it with a chronic, needle‑free plan like SLIT to reduce everyday environmental allergy symptoms long‑term.